The Paris-Saclay Seed Fund has participated in a funding round for Damae Medical, which has developed technology to detect skin cancer without the need for biopsies.

Damae Medical, a health technology spinout of Paris-Saclay University, has secured €2m ($2.2m) in funding from investors including the institution’s Paris-Saclay Seed Fund, according to IT Espresso.

Kurma Partners has also contributed to the funding round, as did Idinvest Partners, News Invest and assorted, unnamed angel investors.

Founded in 2014, Damae Medical has developed technology that combines high-resolution tomographic imagery and algorithms to detect skin cancer without the need for a biopsy.

The technology is based on research conducted by…